"For the primary endpoint, all dose groups of BTX 1503 reduced the number of inflammatory lesions from baseline with the highest efficacy obtained for the 5% BTX 1503 QD group (-11.8 lesions). This corresponds to an average percent reduction of 40.54%. The combined vehicle group result was -11.3 lesions or an average percent reduction of 40.15%."
Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-7
-
- There are more pages in this discussion • 396 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
-0.005(1.32%) |
Mkt cap ! $678.7M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.5¢ | 35.5¢ | $2.388M | 6.527M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 31921 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 132066 | 4 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |